What is Cortaid Cream and how is it used?
Cortaid is an over the counter and prescription medicine used to treat the symptoms of Atopic Dermatitis and Corticosteroid-responsive Dermatoses. Cortaid may be used alone or with other medications.
Cortaid belongs to a class of drugs called Corticosteroids, Topical.
It is not known if Cortaid is safe and effective in children younger than 2 years of age.
What are the possible side effects of Cortaid Cream?
Cortaid Cream may cause serious side effects including:
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- weight gain (especially in your face, upper back and torso),
- slow wound healing,
- thinning skin,
- increased body hair,
- irregular menstrual periods,
- changes in sexual function,
- muscle weakness,
- anxiety, and
Get medical help right away, if you have any of the symptoms listed above.
The most common side effects of Cortaid Cream include:
- skin redness,
- mild burning,
- tingly or prickly feeling,
- changes in skin color, and
- dryness or cracking of treated skin
Tell the doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Cortaid Cream. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. Hydrocortisone is included in this class of synthetic corticosteroid.
Chemically, hydrocortisone is pregna-4-ene3,20-dione,11,17,21-trihydroxy-(11B); its molecular formula is C21H30O5 ; its molecular weight is 362.47; its Chemical Abstract Service (CAS) registry number is 50-23-7. The structural formula is:
Each gram of Hydrocortisone Cream USP 1 % provides 10 mg of hydrocortisone in a nonstaining water washable cream base consisting of stearyl alcohol, glyceryl monostearate, polyoxyl 40 stearate, isopropyl palmitate, paraffin, sorbitan monostearate, glycerin, lactic acid, potassium sorbate and purified water.
Each gram of Hydrocortisone Ointment USP 1% provides 10 mg of hydrocortisone in a white petrolatum base.
DOSAGE AND ADMINISTRATION
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Hydrocortisone Cream USP 1 %
1 o (28.4 g) tube
Hydrocortisone Ointment USP 1 %
1 o (28.4 g) tube
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.
No information provided.
Do not use CORTAID (hydrocortisone cream and ointment 1.0%) near the eyes if you have glaucoma. Treatment with alclometasone, clobetasol, halobetasol propionate and augmented betamethasone dipropionate beyond two weeks consecutively is not recommended. Do not use if there is an infection or sores present on the area to be treated. Though very unlikely, it is possible CORTAID (hydrocortisone cream and ointment 1.0%) will be absorbed into your bloodstream. This may have undesirable consequences that may require additional corticosteroid treatment. This is especially true for children and for those who have used this for an extended period if they also have serious medical problems such as serious infections, injuries or surgeries. This precaution applies for up to one year after stopping use of this drug. Consult your doctor or pharmacist for more details. CORTAID (hydrocortisone cream and ointment 1.0%) should be used cautiously during pregnancy and only if clearly needed. Discuss the benefits and risks with your doctor. Small amounts of CORTAID (hydrocortisone cream and ointment 1.0%) may appear in breast milk. Consult with your doctor before breast-feeding.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systematic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See Pediatric Use below). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Information for the Patient
See PATIENT INFORMATION section.
The following tests may be helpful in evaluating HPA axis suppression: Urinary free cortisol test; ACTH stimulation test.
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
Teratogenic Effects - Pregnancy Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Pediatric patients may demonstrate greater susceptibility to topical corticos- teroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/ or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/ or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Patients using topical corticosteroids should receive the following information and instructions.
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight- fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
Skin Problems and Treatments Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.